Why we wrote this

Wyndly uses an at‑home, finger‑prick dried blood spot (DBS) specimen to measure allergen‑specific IgE (sIgE) for common environmental triggers. Patients and clinicians sometimes ask how DBS compares with a traditional venous blood draw (including in‑home phlebotomy). This page explains assay methods, known performance characteristics, where DBS is sufficient, when venous sampling is preferable, and our service timelines.

What we measure (assay type and clinical question)

• Biomarker: allergen‑specific IgE (sIgE) to environmental allergens (e.g., pollens, dust mites, pet dander, molds).

• Clinical question: sensitization status to relevant aeroallergens to support diagnosis and management of allergic rhinitis/conjunctivitis and related conditions.

• Method: quantitative laboratory immunoassay on a CLIA‑certified platform using eluted capillary whole blood from a DBS card.

• Ordering and details: see Wyndly’s at‑home test product page (Indoor & Outdoor At‑Home Allergy Test).

CLIA context and quality system

• U.S. clinical laboratories must hold the appropriate CLIA certificate for the complexity of testing performed. CLIA establishes quality standards so results are accurate, reliable, and timely across all labs and locations. Laboratories performing moderate/high‑complexity immunoassays operate under a Certificate of Compliance or Accreditation with routine inspections, proficiency testing, and quality controls.

• Why it matters: regardless of whether the sample is DBS or venous serum, CLIA requirements govern assay validation, calibration, controls, reportable ranges, turnaround‑time documentation, and personnel training.

DBS vs venous: what’s the actual analytic difference?

• The immunoassay that quantifies sIgE is the same class of laboratory method in both cases; the difference is the specimen matrix and pre‑analytic handling (DBS card vs serum tube). When validated, modern sIgE methods show strong agreement between capillary/DBS and venous serum for aeroallergen testing. Peer‑reviewed work has demonstrated:

• High correlation of capillary blood IgE with serum IgE, and feasibility of paper‑dried samples for multiplex allergen testing.

• Assay‑to‑assay differences exist across manufacturers (e.g., ImmunoCAP vs IMMULITE vs other systems); decision thresholds (kUA/L) are assay‑specific and should not be interchanged.

• Practical implication: for environmental sIgE panels used to guide avoidance and immunotherapy candidacy, a properly validated DBS workflow provides clinically concordant information for most patients.

Known DBS pre‑analytic strengths and limitations

Strengths

• Patient‑centric sampling at home (no phlebotomy appointment, helpful for children and needle‑averse adults).

• Ambient stability during shipment; analytes are immobilized on filter paper until elution in the lab.

• Very small volume requirement enables testing for dozens of aeroallergens from a single card.

Limitations (and how we mitigate them)

• Hematocrit effect: whole‑blood diffusion on filter paper varies with hematocrit and can bias quantitative recovery if not addressed. Laboratories mitigate via full‑spot extraction, validated punch strategy, hematocrit correction/monitoring, internal controls, and method validation across hematocrit ranges.

• Punch‑location variability: uneven spot distribution can introduce bias; mitigated by validated extraction methods and control materials.

• Extremely low or high total IgE: interpreting very low positive or very high saturated results may benefit from reflex or repeat testing.

When venous draw (including home phlebotomy) is preferable

Choose venous sampling when one or more of the following apply:

• You need larger sample volumes for extensive reflex testing (e.g., component‑resolved diagnostics beyond a fixed aeroallergen panel) or for repeat/duplicate analyses.

• Borderline or discordant results require immediate replication, dilution studies, or orthogonal confirmation on another platform.

• Concurrent lab work (e.g., tryptase, total IgE with serial dilutions, other biomarkers) is ordered during the same draw to streamline care.

• Pre‑analytic concerns exist for DBS (e.g., inadequate spots, smeared cards, extreme hematocrit) and rapid re‑collection is impractical.

When a finger‑prick (DBS) is sufficient—and why Wyndly uses it

Use DBS for most environmental allergy evaluations when the goals are to:

• Identify sensitization to common indoor/outdoor aeroallergens to guide avoidance steps and shared decision‑making around immunotherapy.

• Start/monitor sublingual immunotherapy targeting multiple environmental allergens from a validated panel (no need for large volumes or repeated same‑day replicates).

• Simplify logistics for families, rural patients, frequent travelers, and those with needle phobia.

Performance notes clinicians should know (assay interpretation)

• sIgE measures sensitization, not disease by itself. Positive sIgE must be interpreted with the clinical history and exposure context; negative results have high utility to rule out sensitization to tested allergens.

• Assay cutoffs are platform‑specific. Published decision points (e.g., 0.35 kUA/L positivity; higher thresholds with greater PPV) were derived on specific systems and should not be applied across assays without validation.

• Inter‑assay differences exist. If you intend to trend values over time, use the same laboratory and method where possible.

Sensitization vs clinical allergy: how Wyndly interprets results

• We correlate your sIgE profile with symptom timing, exposures, and geography to determine clinical relevance. Sensitization alone (a low‑level positive) may not explain symptoms; conversely, strong history with negative sIgE prompts reconsideration of different triggers or skin testing.

• For food allergy concerns: Wyndly focuses on environmental allergies. A positive food sIgE denotes sensitization and does not equal a confirmed food allergy; oral food challenge remains the diagnostic gold standard in appropriate settings. We do not use DBS screening to diagnose food allergy.

Timelines and service‑level expectations (typical)

• Kit shipping to you: 2–4 business days from order.

• Lab processing once your card arrives: up to 6 business days.

• Physician review and treatment planning: typically within 1–2 business days after results post.

• References: Wyndly operational timelines are documented on our tracking and patient FAQ pages (see Order tracking & timelines and Patient FAQs).

One‑glance comparison

Consideration	Finger‑prick DBS	Venous draw / home phlebotomy
Collection	At home; finger‑stick onto filter paper	Trained phlebotomist; serum tube(s)
Volume available	Low; optimized for fixed aeroallergen panel	High; supports reflex/component testing and repeats
Shipping & stability	Ambient; robust when validated	Refrigerated/frozen per lab policy
Pre‑analytic risks	Hematocrit and punch‑location bias if unmitigated	Hemolysis/lipemia; transport temperature
Turnaround (typical)	Total door‑to‑door ≈ 1–2 weeks including shipping	Similar lab time; draw logistics may add scheduling time
Best for	Environmental panels, telehealth workflows, pediatrics, needle‑averse	Broad workups, component‑resolved testing, high‑stakes confirmation

Our escalation policy (when we suggest venous confirmation)

We may recommend a venous sample when: (1) a result sits near a medical decision threshold and would change management; (2) results are discordant with strong clinical history; (3) component‑level questions arise (e.g., distinguishing true sensitization from cross‑reactivity) requiring additional assays; or (4) repeatability is needed immediately.

How to order (and what you get)

• Start with Wyndly’s at‑home test (product page). A board‑certified physician reviews results with your history to decide next steps. If venous sampling is indicated, we’ll explain your options, including local labs or home phlebotomy.

References (selected)

External references (key takeaways summarized above; links provided where allowed in Wyndly’s Learning Center):

• CLIA program background and certificate types; federal oversight by CMS/CDC/FDA.

• Assay platforms and inter‑assay variability: comparisons of ImmunoCAP vs IMMULITE; assay‑specific decision points; consistency considerations when trending results.

• DBS feasibility for allergy serology: publications demonstrating high correlation of capillary/DBS and serum IgE and successful use of paper‑dried samples in multiplex allergen testing; known hematocrit and punch‑location effects and laboratory mitigations.

• Sensitization vs clinical allergy: practice‑parameter guidance emphasizing that positive sIgE denotes sensitization and must be interpreted with history; oral food challenge as gold standard for food allergy diagnosis.

Wyndly resources

• Indoor & Outdoor At‑Home Allergy Test

• Order tracking & timelines

• Patient FAQs

If you’re a clinician and want method validation details or to discuss a venous confirmation pathway for a specific case, contact our medical team at care@wyndly.com.